Boston Scientific has secured CE Mark approval for magnetic resonance imaging (MRI) conditional labelling for its current family of Extended Longevity (EL) and MINI implantable cardioverter defibrillator (ICD) and X4 cardiac resynchronisation therapy defibrillator (CRT-D) systems.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The revised labelling ensures that future patients and those already implanted with the systems are able to undergo MRI scans if indicated.

Boston Scientific Rhythm Management division executive vice-president Joe Fitzgerald said: "We are pleased to combine broader imaging options with our long-lasting, high-voltage portfolio, offering additional value to our exclusive EnduraLife battery technology for European physicians and their patients.

"We are seeking regulatory approvals for revised labelling and updated software for these systems in major markets by 2017."

"We are seeking regulatory approvals for revised labelling and updated software for these systems in major markets by 2017."

Referred to as ImageReady MR Conditional devices, the new system labelling specifies conditions under which the systems are deemed safe for use in a MRI setting.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

With the addition of ImageReady capabilities to all high-voltage products currently marketed, including Autogen, Dynagen, Inogen and Origen devices, Boston Scientific now has the largest portfolio of MRI-compatible products in Europe.

Capabilities were also incorporated into ACUITY X4 quadripolar LV leads, Ingevity and Fineline II pacing leads, as well as Reliance 4-Site and 4-Front defibrillator leads.

While patients with implantable cardiac devices have access to an array of diagnostic imaging, including x-rays and CT scans, the company’s systems were not evaluated as MRI conditional.

Italian Association of Pacing and Arrhythmias president Gianluca Botto said: "While the broader imaging compatibility will be important for some patients, I still expect device longevity and the ability to mitigate risk of complications to be the most critical factors in choosing the best system for each patient."

According to the company, MRI compatibility has not received regulatory approval in all geographies.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact